Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel
NYSE:ANRO

Alto Neuroscience Q3 2026 Earnings Date & Estimates

Alto Neuroscience logo
$22.68 +0.97 (+4.47%)
Closing price 03:59 PM Eastern
Extended Trading
$22.63 -0.05 (-0.22%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alto Neuroscience is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 12, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Alto Neuroscience in Q3 2026

Alto Neuroscience is expected to post earnings of -$0.6726 per share. In the same quarter a year earlier Alto Neuroscience reported -$0.52 per share. Alto Neuroscience last reported on August 12, 2026, posting -$0.65 per share and beating the -$0.7345 consensus estimate. Alto Neuroscience has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.6726
Prior-Year EPS
-$0.52

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.65 (Beat by +$0.0845)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Alto Neuroscience Q3 2026 Earnings FAQ

Alto Neuroscience (NYSE:ANRO) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Alto Neuroscience's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Alto Neuroscience to post earnings of -$0.6726 per share for Q3 2026.

Alto Neuroscience Earnings Headlines

Alto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To Hold
 |  seekingalpha.comhttps://seekingalpha.com/article/4954537-alto-neuroscience-doubts-around-depression-candidate-merit-downgrade-to-hold
Alto Neuroscience (NYSE: ANRO) CFO sells shares under trading plan
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085873
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
October 15 at 1:00 AM  |  Weiss Ratings (Ad)
Alto Neuroscience (NYSE:ANRO) Stock Price Down 5.6% Following Insider Selling
October 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083636
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
September 9, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260909519463/en/alto-neuroscience-announces-participation-in-upcoming-investor-conferences/
Alto Neuroscience Promotes Smith to President, CFO
August 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/alto-neuroscience-promotes-smith-to-president-cfo?utm_source=marketbeat.com&utm_medium=referral
See More Alto Neuroscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alto Neuroscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alto Neuroscience and other key companies, straight to your email.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and neurological disorders. The company seeks to use neuroscience, digital health tools and biological and behavioral biomarkers to identify patient subgroups that may respond to specific treatments.

Alto’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions. Its development programs are designed to address limitations of conventional psychiatric treatment by matching therapies to patient characteristics and measuring treatment response through objective data. The company’s drug candidates remain investigational and are subject to clinical and regulatory evaluation.

Founded by psychiatrist and neuroscientist Amit Etkin, Alto Neuroscience is headquartered in the United States and conducts its research and clinical development activities through collaborations and clinical studies primarily involving U.S. patients and institutions. The company is listed on the New York Stock Exchange under the symbol ANRO.

View Alto Neuroscience Profile
Earnings Tools